INTRODUCTION
One of the most feasible approaches for achieving a prolonged and predictable drug delivery in the GI tract is to control the gastric residence time (GRT), by using gastro retentive dosage forms (GRDFs). GRDF's can remain in the gastric region for several hours and hence prolong the gastric residence time of drug. GRDF's offer several advantages over immediate release dosage form, including the minimization of fluctuations in drug concentration in plasma, and at the site of action over prolonged periods of time, resulting in optimized therapeutic efficiencies and reduce the side effect, reduction of total dose administered, (while providing similar therapeutic effect) and reduction of administration frequency, leading to improved patient compliances. Various approaches have been pursued to increase the retention of an oral dosage form in the stomach among which low density floating drug delivery systems forms major drug delivery devices. These systems maintain a density of less than 1.004 gm/cm 3 which makes them float on the gastric contents. The various types of buoyant preparation include hollow microsphere (micro balloons), granules powder, capsule, tablet (pills) and laminated films.
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Hollow microsphere floats immediately upon contact with gastric fluid and gives promising approaches for increasing the bioavailability of drugs with absorption windows in upper small intestine and stomach. However, immediate floating can only be achieved, when the density of the device is lower than gastric fluid.
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Glipizide is a second-generation oral sulfonylurea hypoglycemic agent used in lowering the blood sugar levels in patients with non-insulin dependent diabetes mellitus. Gastrointestinal absorption is uniform, rapid and essentially complete with peak plasma concentration occurring 1 to 3 hrs after a single dose. It is extensively bound to plasma proteins and a half-life of approximately 2 to 4 hrs. In order to maintain therapeutic plasma concentration, the drug must be administered frequently by oral route in divided doses which leads to fluctuations in plasma drug levels.
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To overcome inherent drawbacks associated with conventional dosage forms of Glipizide, an attempt is being made to develop an alternative drug delivery system in the form of floating microspheres.
MATERIALS & METHODS

Preparation
of Floating Microspheres of Glipizide: 10, 11 For present study, acrylic polymer Eudragit combined with Hydroxy Propyl Methyl Cellulose is used with the active ingredient for preparation of floating microspheres (Table 1) .
Glipizide floating microspheres were prepared using varying concentrations of Eudragit RS100 and HPMC by Emulsification solvent diffusion method. The drug to polymer ratio used to prepare the different formulations was 1:7. The drug and polymer mixture is dissolved in a mixture of ethanol (8 ml) and dichloromethane (8 ml) and dropped into 0.75% polyvinyl alcohol solution (200 ml). The solution was stirred with a propeller-type agitator at 40° C temperature for 1 hour at 300 rpm. The formed floating microspheres were passed through sieve no 12 and washed with water and dried at room temperature in a desiccator. 
Evaluation of Drug Loaded Floating Microspheres:
Percentage Yield:
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The prepared microspheres were collected and weighed from different formulations. The measured weight was divided by the total amount of all nonvolatile components which were used for the preparation of the microspheres.
% Yield = Actual weight of product/ Total weight of drug and polymer x 100
Particle size analysis: [13] [14] [15] The sizes of floating microspheres were measured by using an optical microscope, and the mean particle size was calculated by measuring nearly 200 particles with the help of a calculated ocular micrometer.
Buoyancy behavior of Floating microsphere:
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The floating ability was determined using USP dissolution tester apparatus II (Paddle method). About 100 mg of the floating microsphere were placed in 0.1 N Hcl (300 ml) containing 0.02% of Tween 20. The mixture was stirred with paddle at 100 rpm. The layer of buoyant microspheres was taken out and separated by filtration at 1, 2, 4 and 6 hours. The collected microspheres were dried in a desiccator over night. The percentage of microspheres was calculated by the following equation:
% Floating = Weight of floating microspheres/ Initial weight of microspheres x 100
Encapsulation Efficiency and Drug Loading: 17, 18 The amount of drug encapsulated in floating microspheres was determined by sonicating known amount of microspheres in ethanol for 15 min and 1 ml of this solution was withdrawn and diluted to 50 ml with Sample was fixed on carbon tape and fine gold sputtering was applied in a high vacuum evaporator. The acceleration voltage was set at 30KV during scanning. Microphotographs were taken on different magnification and higher magnification (500X) was used for surface morphology.
Drug Polymer Interaction (FT-IR) Analysis:
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The Fourier transform infra-red analysis was conducted for the analysis of drug polymer interaction and stability of drug during microencapsulation process. Fourier transform infra-red spectrum of pure Glipizide, Eudragit RS 100, HPMC, Physical mixture and floating microspheres (formulation) were recorded.
In-vitro Release Studies:
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A weighed amount of floating microspheres equivalent to 100 mg Glipizide were dispersed in 900 ml of 0.1 N Hcl (pH 1.2) maintained at 37 ± 0.5°C and stirred at 100 rpm. One ml of sample was withdrawn at predetermined intervals and was suitably diluted with 0.1 N Hcl and analyzed spectrophotometrically at 276 nm to determine the concentration of drug present in the dissolution medium.
RESULTS & DISCUSSION:
In the current research, floating microspheres loaded with Glipizide were developed and evaluated.
IR Studies
The physical mixture showed identical spectrum with respect to the spectrum of the pure Glipizide, indicating there is no chemical interaction between the drug molecule and polymers used. (Fig 1-5 Fig 6) .
Particle Size Analysis:
The mean particle size of floating microspheres was in range of 617.42-882.75 μm ( Table 2) . As the particle size increased the rate of release decreased showing good controlled release nature along with optimum buoyancy character.
Percent Encapsulation Efficiency and Percent Drug loading:
The drug entrapment efficacies and percent drug loading of the prepared microspheres were in the range of 60.24 to 90.68% w/w and 18.21 to 30.85% (Table 2 & Fig 6) . Drug entrapment efficacy and drug loading slightly decreased with increased HPMC content and decreased Eudragit ratio in microspheres. This can be attributed to permeation nature of HPMC that could facilitate the diffusion of part of entrapped drug to surrounding medium during preparation of hollow microspheres.
Buoyancy Character of Microspheres:
Floating ability was found to be altered according to Eudragit and HPMC ratio. F 1 -F 4 formulations showed best floating ability with 80.64 to 93.74% and formulations F 5 -F 8 showed less floating ability of 58.39 to 71.82% in 6 hours ( Table 2 ). The floating ability of microspheres is decreased by increasing the HPMC ratio in the formulations. 63.67 F 4 74.96 F 5 93.81 F 6 94.29 F 7 95.65 F 8 96.82 
CONCLUSION:
By studying all the experimental results floating microspheres encapsulated with Glipizide can be successfully formulated by emulsification solvent diffusion method. By incorporating hydrophilic polymer such as HPMC in the shell of microspheres, the rate of drug release can be enhanced. Characteristic property of floating microsphere includes high buoyancy and sufficient release of drug in gastric contents. Formulation F 4 showed best appropriate balance between buoyancy and drug release rate, which can be considered as a best fit for floating microspheres.
